A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Duvelisib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2016 Planned number of patients changed from 26 to 32.